The cytochromes P450 are a multigene super-family of enzymes, existing as multiple forms, which metabolise a wide variety of xenobiotics and endogenous compounds including steroid hormones and arachidonic acid (Gonzalez, 1990; Nebert & Gonzalez, 1987; Nebert et al., 1989; Fitzpatrick & Murphy, 1988) . This group of enzymes has a central role in activating and detoxifying chemical carcinogens and anticancer drugs (Guengerich, 1988) . The major forms of cytochrome P450 involved in xenobiotic metabolism (cytochrome P450 families I, II and III) are predominantly found in liver. Specific forms of cytochrome P450 have been identified in a variety of extra hepatic tissues including lung, kidney, small intestine and steroidogenic tissues.
The expression of cytochromes P450 and their associated mono-oxygenase activities have been extensively studied in chemically induced liver tumours in animals (Buchmann et al., 1985; Roomi et al., 1985; Stout & Becker, 1986) Cytochrome P450IA expression was demonstrated immunocytochemically with a murine monoclonal antibody (RM3), which recognises cytochrome P450IA. The monoclonal antibody RM3 was produced in mice using highly purified rat liver cytochrome P450IA1 as described elsewhere (Barnes et al., 1987 Twenty-one of the 54 tumours studied (39%) showed positive imrmiunoreactivity for cytochrome P4SOIA (Figures 1 and  2) . The immunostaining was present within the cytoplasm of the tumour cells and there were no nuclear staining. The immunostaining was present only in areas of invasive carcinoma, and there was no immunoreactivity of tumour cells or foci of ductal carcinoma in situ. In addition there was no staining of adjacent normal breast epithelium (Figure 3) , areas of epithelial hyperplasia, chronic inflammatory cells associated with tumour cells, mast cells and connective tissue. Specific staining of tumour cells was abolished when the anti cytochrome P450 antibody was omitted from the immunocytochemical procedure.
There was no correlation between cytochrome P450 expression, tumour grade (three grades: chi-squared = 3.03, P >0.1), oestrogen receptor status (two categories, positive and negative: chi squared = 0.2, P >0.1) or smoker: chi squared = 0.2, P > 0.1).
This report describes the constitutive expression of a specific form of cytochrome P450, cytochrome P45OIA, in human breast cancer. Cytochrome P450XIXA1 (P450 aromatase) has previously been identified in breast cancer (Lipton et al., 1987) although it has also been identified in non-neoplastic breast tissue (Newton et al., 1986) in contrast with the current report of cytochrome P4501A which appears to be present only in malignant tumour cells. Cytochrome P4501A is a major family of cytochrome P450 consisting of two members, cytochrome P4501A1 and cytochrome P450IA2, and the monoclonal antibody used in this study recognises rat cytochrome P4501A1 and not rat cytochrome P4540IA2 and recognises a single band on immunoblots of human liver microsomes, although it is not yet known which human cytochrome P4501A family member it recognises. The monoclonal antibody RM3 does not recognise purified human cytochrome P450hA7 (a member of the cytochrome P450IIIA family) or P45OhB (a member of the P450IIC family) (manuscript in preparation).
Cytochrome P4501A expression was demonstrated using a specific and sensitive technique which has the spatial resolution to identify even a few cells expressing cytochrome P450IA. Proteolytic enzyme digestion was not performed prior to immunostaining as we have shown that cytochrome P450 immunoreactivity is abolished by proteolytic enzyme activity (Murray et al., 1987a) . Cytochrome P4501A activity was identified only in tumour cells and 39% of tumours displayed expression of cytochrome P4501A. The expression of cytochrome P4501A was present only in areas of invasive tumour, there was no expression of cytochrome P4501A in foci of ductal carcinoma in situ or non-neoplastic breast epithelium. The expression of cytochrome P450IA did not appear to depend on the degree of differentiation of the tumour since there was no correlation with the tumour grade. Similarly there was no correlation between cytochrome P4501A expression and smoking habits although smoking may induce expression of this family of cytochrome P450 in liver (loannides & Parke, 1990 ) and extrahepatic tissue.
There have been few studies of cytochrome P450 in human tumours and this is the first report to describe the constitutive expression of a specific form of cytochrome P450 in a tumour when there is no expression of cytochrome P450 in the surrounding non-tumour tissue. These findings contrast with the decreased expression of cytochrome P450 observed in chemically induced experimental liver tumours (Buchmann et al., 1985; Roomi et al., 1985; Stout & Becker, 1986) and similarly two previous studies of small numbers of hepatocellular carcinomas have shown generally decreased expression of cytochrome P450IIIA in tumour cells (El Mouelhi et al., 1987; Murray et al., 1987b ) compared with surrounding nontumour liver which has a high concentration of cytochrome P450IIIA. In addition, cytochrome P45OIA1 expression has been described in lung cancers from cigarette smokers and there was also expression of cytochrome P4501A1 in nontumour lung tissue (McLemore et al., 1990) . Cytochrome P4501A is a major form of cytochrome P450 and one of its functions is to catalyse the conversion of 17-f-oestradiol (oestrogen) to 2-hydroxyoestradiol which is essentially devoid of biological activity (Graham et al., 1988) . Induction of expression of this form of cytochrome P450 activity in a human breast cancer line has been shown to have a marked anti-oestrogenic effect and thus inhibit growth of tumour cells (Gierthy et al., 1988; Schneider et al., 1984) . Therefore the presence of cytochrome P4501A in breast cancers could act as a novel anti-oestrogen due to the intratumour metabolism of oestrogen. Thus the expression of cytochrome P4501A in breast cancer may have implications for the treatment of those breast cancers whose growth is oestrogen dependent. The presence of cytochrome P450IA might potentially be used as a marker of a group of breast cancers which will respond to a particular type of therapy.
